Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

Autor: Linder S; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hoogstraat M; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Stelloo S; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Eickhoff N; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Schuurman K; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Barros H; Division of Urology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Alkemade M; Core Facility Molecular Pathology and Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Bekers EM; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Severson TM; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Sanders J; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Huang CF; Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada., Morova T; Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada., Altintas UB; School of Medicine, Koç University, Istanbul, Turkey.; Koç University Research Centre for Translational Medicine (KUTTAM), Koç University, Istanbul, Turkey., Hoekman L; Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Kim Y; Department of Pathology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam, the Netherlands., Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; The Eli and Edythe L. Broad Institute, Cambridge, Massachusetts., Sjöström M; Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Zaalberg A; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hintzen DC; Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Jong J; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Kluin RJC; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Rink I; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Giambartolomei C; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Pasaniuc B; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Altelaar M; Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, Utrecht, the Netherlands., Medema RH; Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Feng FY; Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Department of Urology, University of California, San Francisco, San Francisco, California., Zoubeidi A; Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; The Eli and Edythe L. Broad Institute, Cambridge, Massachusetts., Wessels LFA; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Faculty of EEMCS, Delft University of Technology, Delft, the Netherlands., Butler LM; Freemasons Centre for Male Health and Wellbeing, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.; South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia., Lack NA; Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.; School of Medicine, Koç University, Istanbul, Turkey.; Koç University Research Centre for Translational Medicine (KUTTAM), Koç University, Istanbul, Turkey., van der Poel H; Division of Urology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Urology, Amsterdam University Medical Centers, Amsterdam, the Netherlands., Bergman AM; Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Zwart W; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands.

Publikováno v: Cancer discovery [Cancer Discov] 2022 Sep 02; Vol. 12 (9), pp. 2074-2097.